Details:

Alternative Title:
Diabetes Care
Personal Author:
Li, Rui ; Zhang, Ping ; Barker, Lawrence E. ; Hoerger, Thomas J. ;
Li, Rui ; Zhang, Ping ; Barker, Lawrence E. ; Hoerger, Thomas J. ; Less -
Description:
OBJECTIVE To assess the long-term cost-effectiveness of aspirin use among adults aged ≥40 years with newly diagnosed type 2 diabetes. RESEARCH DESIGN AND METHODS We used a validated cost-effectiveness model of type 2 diabetes to assess the lifetime health and cost consequences of use or nonuse of aspirin. The model simulates the progression of diabetes and accompanying complications for a cohort of subjects with type 2 diabetes. The model predicts the outcomes of type 2 diabetes along five disease paths (nephropathy, neuropathy, retinopathy, coronary heart disease, and stroke) from the time of diagnosis until age 94 years or until death. RESULTS Over a lifetime, aspirin users gained 0.31 life-years (LY) or 0.19 quality-adjusted LYs (QALYs) over nonaspirin users, at an incremental cost of $1,700; the incremental cost-effectiveness ratio (ICER) of aspirin use was $5,428 per LY gained or $8,801 per QALY gained. In probabilistic sensitivity analyses, the ICER was <$30,000 per QALY in all of 2,000 realizations in two scenarios. CONCLUSIONS Regular use of aspirin among people with newly diagnosed diabetes is cost-effective.
Subject:
[+]
Adult
Aged
Aged, 80 And Over
Aspirin
Cost-Benefit Analysis
Diabetes Mellitus, Type 2
Female
Humans
Hypoglycemic Agents
Male
Middle Aged
Original Research
Time Factors

Source:
Diabetes Care. 33(6):1193-1199.
Document Type:
Journal Article ;
Collection(s):
CDC Public Access
Main Document Checksum:
[+]
urn:sha256:dcbd66531db8bc365f989a95639c436a8fc120d9badb2cab0fbfc950652e5c52
File Type:

Supporting Files

• 	license.txt	txt
  	zdc0061082890001.gif	gif
  	zdc0061082890001.jpg	jpeg
  	zdc1193.nxml	txt

More +